Goldman Sachs
Adaptive Bio Initiates Strategic Review, Considers Separation of MRD, Immune Medicine Businesses
Premium
While reporting its Q3 earnings results, Adaptive said it hired Goldman Sachs to perform "a review of strategic alternatives" for its MRD and immune medicine businesses.
Myriad Genetics to Raise $110M in Public Stock Offering
The Salt Lake City-based genetic testing and precision medicine company is offering 6,470,588 shares of its common stock at a public offering price of $17 per share.
PerkinElmer Reaches Deal for $1.5B Credit Facility
The agreement is for a new credit facility, which replaces one from 2019 that provided for a $1 billion unsecured revolving credit facility.
PerkinElmer Enters $500M Credit Facility
The proceeds will be used to pay, in part, PerkinElmer's $5.25B acquisition of BioLegend, announced last month.
Sema4 Raises $121M in Series C Financing Round
BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.